RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Rademikibart for Asthma Acute

Q: Is NCT07705737 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07705737?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07705737?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Official registry: https://clinicaltrials.gov/study/NCT07705737 · Connect Biopharm LLC · enrollment listed as 40

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Rademikibart. The registry lists allocation as na. A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

They plan to enroll about 40 people at 3 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation

Interventions: Rademikibart

Primary outcome (registry wording): Change from baseline in post-BD FEV1

Who it is for (from inclusion criteria)

Ages 18 Years to 85 Years
Body weight of ≥40 kg and body-mass index (BMI) ≤45 kg/m2 at SV1a
Physician-diagnosed asthma
Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication
Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids
Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb
Current acute asthma exacerbation requiring an urgent healthcare visit for treatment
Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation

Who the registry excludes

Regular use of immunosuppressive medication
Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension
Current or former smoker, with a smoking history of ≥5 pack-years if \<30 years old or ≥10 pack-years if ≥30 years old
COPD and other clinically significant pulmonary disease other than asthma
Known or suspected history of immunosuppression
History of known immunodeficiency disorder or hepatitis B or C
History of alcohol abuse and/or drug abuse

Public study contact (from the registry)

Radha Adivikolanu

213-522-7990

clinical209@connectpharm.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

3 listed

Columbus Clinical Services, LLC — Miami, Florida (active_not_recruiting)
Pharmax Research of South Florida, Inc. — Miami, Florida (recruiting)
Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory — St Louis, Missouri (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Role of Genetic Factors in the Development of Lung Disease

This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.

NCT00001532 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

RecruitingPhase 1Boston, Massachusetts

Phase 1: testing Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage for Asthma

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation.

NCT00595491 · Official ClinicalTrials.gov record · Benjamin Medoff

RecruitingNot a traditional drug phaseNew York, New York

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.

NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

FAQ about this NCT record

Is NCT07705737 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07705737?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07705737?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary